Mangoceuticals, Inc. announced that it has received a Notice of Acceptance for Australian Patent Application No. 2020235666, which is the National Phase of International Application No. PCT/US2020/022903.

Following the company?s recent receipt of a Notice of Allowance from Japan, this additional patent acceptance from Australia forges a significant milestone following MangoRx?s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies on April 24, 2024. The Notice of Acceptance covers the proprietary formulation and application methods designed to combat a wide range of infections, including common colds, respiratory diseases, and orally transmitted infections such as human papillomavirus (HPV). Acceptance of the application will officially be published in the Australian Official Journal of Patents on June 6, 2024.

The patented technology is designed to prevent illnesses acquired through the oral cavity and pharynx using an orally available solution, such as toothpaste, oral dissolvable tablets (ODT), lozenges, or mouthwash. The unique formulation features GALALCOOL®, zinc protoporphyrin IX, and select tannins, which work synergistically to inhibit various pathogens, offering comprehensive protection against respiratory infections. This expansion aligns with MangoRx?s mission to enhance well-being through innovative health solutions.

The official patent deed is anticipated to be issued on or around September 6, 2024 and is subject to issuance upon receipt of a Notice of Opposition within three months from the acceptance advertisement.